Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2018 | The current treatment landscape for penile cancer

With the involvement of so many genetic and molecular alterations in cancer, it is nearly impossible to know what pathway to target for a clinically significant outcome that also has a low toxicity level. In this interview, Lisa Pickering, MRCP, PhD, of The Royal Marsden NHS Foundation Trust, London, UK, speaking from the Genitourinary Cancers Symposium, in San Francisco, CA, objectively compares retrospective and prospective studies for penile cancer, emphasizing the lack of the prospective studies. She discusses recent trials, including HER-Uro01 (NCT01728233) and the large-scale InPACT study (NCT02305654).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.